Debra Ondeyka
Merck & Co.
22 Papers
181 Citations
Debra Ondeyka is an academic researcher from Merck & Co.. The author has contributed to research in topics: Angiotensin receptor & Angiotensin II. The author has an hindex of 10, co-authored 22 publications.
Chat about Author
Papers
Imidazo[4,5-b]pyridine-based AT1 / AT2 angiotensin II receptor antagonists
Nathan B. Mantlo,Dooseop Kim,Debra Ondeyka,Raymond S.L. Chang,Raymond S.L. Chang,Salah D. Kivlighn,Salah D. Kivlighn,Peter K. S. Siegl,Peter K. S. Siegl,William J. Greenlee +9 more
TL;DR: The structure-activity relationships of 6-amido-imidazol-based angiostensin II antagonists demonstrate that high affinity for the AT1 and AT2 receptors is largely dependent upon the R1 and R4 substituents.
32
A nonpeptidic agonist ligand of the human C5a receptor: Synthesis, binding affinity optimization and functional characterization
S. E. De Laszlo,Eric E. Allen,Bing Li,Debra Ondeyka,Ralph A. Rivero,Lorraine Malkowitz,C J Molineaux,Salvatore J. Siciliano,Martin S. Springer,William J. Greenlee,Nathan B. Mantlo +10 more
TL;DR: The structural optimization for binding affinity and attempted modification of agonist function of a nonpeptide ligand of the human C5a receptor is described.
25
Patent
Diaryl substituted alkanes
Lin Chu,Bing Li,Anthony Ogawa,Hyun O. Ok,Debra Ondeyka,Minal Patel,Rosemary Sisco,Feroze Ujjainwalla,Jinyou Xu +8 more
- 06 Apr 2007
TL;DR: The instant invention provides compounds of Formula (II) which are 5-lipoxygenase activating protein inhibitors as mentioned in this paper, which are useful as anti-atherosclerotic, anti-asthmatic, anti allergic, antiinflammatory and cytoprotective agents.
22
Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors
Lin Chu,Helen M. Armstrong,Linda L. Chang,Amy F. Cheng,Lawrence F. Colwell,Jisong Cui,Jilly F. Evans,Amy Galka,Mark T. Goulet,Nancy S. Hayes,Jane Lo,John G. Menke,Hyun O. Ok,Debra Ondeyka,Minal Patel,Grace M. Quaker,Heather L. Sings,Stephanie L. Witkin,Annie Zhao,Feroze Ujjainwalla +19 more
TL;DR: A search for a suitable replacement for the central norbornyl scaffold presented in the recently disclosed novel FLAP inhibitors is herein described, as well as the SAR study performed on the endo and exo-aryl groups.
21